<?xml version='1.0' encoding='utf-8'?>
<document id="17594245"><sentence text="Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent."><entity charOffset="58-69" id="DDI-PubMed.17594245.s1.e0" text="fluticasone" /></sentence><sentence text="A 14-year-old female with perinatally acquired HIV on boosted protease inhibitor (PI) therapy with atazanavir and ritonavir rapidly developed cushingoid features with excessive weight gain and moon facies within 2 weeks of receiving inhaled fluticasone/salmeterol for asthma treatment"><entity charOffset="99-109" id="DDI-PubMed.17594245.s2.e0" text="atazanavir" /><entity charOffset="114-123" id="DDI-PubMed.17594245.s2.e1" text="ritonavir" /><entity charOffset="241-252" id="DDI-PubMed.17594245.s2.e2" text="fluticasone" /><entity charOffset="253-263" id="DDI-PubMed.17594245.s2.e3" text="salmeterol" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e0" e2="DDI-PubMed.17594245.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e0" e2="DDI-PubMed.17594245.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e0" e2="DDI-PubMed.17594245.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e0" e2="DDI-PubMed.17594245.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e1" e2="DDI-PubMed.17594245.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e1" e2="DDI-PubMed.17594245.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e1" e2="DDI-PubMed.17594245.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e2" e2="DDI-PubMed.17594245.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17594245.s2.e2" e2="DDI-PubMed.17594245.s2.e3" /></sentence><sentence text=" Soon after discontinuing PIs and inhaled steroid, she required hospitalization for dyspnea, headache, muscle weakness, and extreme fatigue requiring hydrocortisone replacement therapy for presumed adrenal insufficiency"><entity charOffset="42-49" id="DDI-PubMed.17594245.s3.e0" text="steroid" /><entity charOffset="150-164" id="DDI-PubMed.17594245.s3.e1" text="hydrocortisone" /><pair ddi="false" e1="DDI-PubMed.17594245.s3.e0" e2="DDI-PubMed.17594245.s3.e0" /><pair ddi="false" e1="DDI-PubMed.17594245.s3.e0" e2="DDI-PubMed.17594245.s3.e1" /></sentence><sentence text=" Cushing syndrome and adrenal suppression were very likely caused by elevated steroid systemic concentrations resulting from the cytochrome p450 interaction between the protease inhibitors and fluticasone"><entity charOffset="78-85" id="DDI-PubMed.17594245.s4.e0" text="steroid" /><entity charOffset="193-204" id="DDI-PubMed.17594245.s4.e1" text="fluticasone" /><pair ddi="false" e1="DDI-PubMed.17594245.s4.e0" e2="DDI-PubMed.17594245.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17594245.s4.e0" e2="DDI-PubMed.17594245.s4.e1" /></sentence><sentence text=" The Naranjo probability scale score of 5 suggests that the event was probably drug related" /><sentence text=" This is the first case report of fluticasone and PI-induced Cushing syndrome and adrenal suppression in a pediatric patient without a history of recent or concomitant treatment with systemic steroid therapy"><entity charOffset="34-45" id="DDI-PubMed.17594245.s6.e0" text="fluticasone" /><entity charOffset="192-199" id="DDI-PubMed.17594245.s6.e1" text="steroid" /><pair ddi="false" e1="DDI-PubMed.17594245.s6.e0" e2="DDI-PubMed.17594245.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17594245.s6.e0" e2="DDI-PubMed.17594245.s6.e1" /></sentence><sentence text=" Additionally, this case is unique as it is the most rapid (&lt;2 weeks) presentation documented, thus far" /><sentence text=" Health care professionals should be conscious of this important drug-drug interaction in HIV-infected children and adolescents and be aware that rapid onset of hypercortisolism and adrenal suppression are possible" /><sentence text="" /></document>